Announcements Trials
Browse Landscape

Status

Completed 5Withdrawn 1

Sponsor Class

INDUSTRY 6

Study Type

Observational 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Prostatic Neoplasms 22Prostatic Neoplasms, Castration-Resistant 6Neoplasm Metastasis 4Breast Neoplasms 3Neoplasms 2Multiple Myeloma 2Metastatic Castration-resistant Prostate Cancer 2Hormone Refractory Prostate Cancer 2Bone Metastatic Castration-resistant Prostate Cancer 2Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1Fractures, Bone 1Castration-resistant Prostate Cancer 1Castrate-Resistant Prostate Cancer 1Carcinoma, Non-Small-Cell Lung 1Bone Neoplasms 1Bone Metastases 1Bone Diseases 1

Interventions

enzalutamide 14Docetaxel 7radium Ra 223 dichloride 6Abiraterone Acetate 6Prednisone 5darolutamide 4abiraterone 3olaparib 2niraparib 2atezolizumab 2apalutamide 2zimberelimab 1xentuzumab 1tasquinimod 1sacituzumab govitecan 1sabizabulin 1quemliclustat 1ipatasertib 1ibrutinib 1gedatolisib 1gallium 68 PSMA-11 1fludrocortisone acetate 1cabazitaxel 1Rosuvastatin Calcium 1Radium-223 1Pluvicto 1Pioglitazone 1Nivolumab 1JNJ-64619178 1JNJ-64264681 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Prostatic Neoplasms, Castration-Resistant × radium Ra 223 dichloride × Clear all
NCT02803437 2025-07-10

Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases

Bayer

Completed
334 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT02398526 2021-11-02

PARABO

Bayer

Completed
363 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT02450812 2021-11-02

URANIS

Bayer

Completed
86 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT03563014 2020-05-20

BELFIGO

Bayer

Completed
164 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT02899104 2020-03-31

Navigant

Bayer

Completed
200 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT03325127 2018-10-31

Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study

Bayer

Withdrawn
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡